Thermo Fisher Scientific, Inc.
detachable dynabeads
detachable dynabeads
detachable dynabeads
detachable dynabeads
detachable dynabeads

Thermo Fisher Accelerates Cell Therapy Manufacturing With Next-Generation Platform of Detachable Dynabeads

Dec. 7, 2023
The breakthrough Gibco CTS Detachable Dynabeads platform delivers process flexibility and scalability with the first active release mechanism of its kind for clinical trial and commercial manufacturing use.

Thermo Fisher Scientific Inc.'s Gibco CTS Detachable Dynabeads is a next-generation platform of Dynabeads that offers the first active release mechanism of its kind for clinical trial and commercial manufacturing use.

The active release mechanism uses a release buffer that lets users actively detach Dynabeads from a target cell at any point during the manufacturing process. As a result, CTS Detachable Dynabeads help drive manufacturing cost savings while delivering high cell purity, yield, and viability.

These manufacturing benefits can help cell therapy developers get more life-changing treatments to patients faster, especially for those diagnosed with complex diseases such as blood cancers.

CTS Detachable Dynabeads offer process flexibility, compatibility with automation, and scalability through its differentiating active release mechanism. This functionality, for cGMP and clinical use, helps users achieve greater control of their process with the ability to consistently deliver target cells with the desired characteristics for their therapy. Cell recovery, phenotype, and viability for downstream steps within the workflow are also optimized through this platform. These advantages are critical for cell therapy manufacturers who need to scale their manufacturing while maintaining consistent performance as they transition from process development to clinical trials and commercial manufacturing.